Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Paroxysmal Atrial Tachycardia Market size was over USD 6.4 billion in 2024 and is expected to reach USD 15.2 billion by the end of 2037, registering at a CAGR of 6.9% during the forecast timeline, i.e., 2025-2037. In 2025, the industry size of paroxysmal atrial tachycardia is evaluated at USD 6.8 billion.
Paroxysmal atrial tachycardia (PAT) is a type of arrhythmia characterized by unexpected incidents of swift heartbeats instigating in the atria. In an article published by NLM in February 2024, the prevalence rate of this condition effectively ranges between 0.3% to 0.4% globally. It is significantly higher among symptomatic individuals with paroxysmal supraventricular tachycardia (PSVT) as well as those with primary and structural heart diseases. However, the availability of advanced treatment options safeguards accurate interventions and supports personalized patient care, which is readily driving the paroxysmal atrial tachycardia market growth worldwide.
The use of pacemakers in case of heart failure is another factor responsible for the growth of the market internationally. As a result, there is continuous export and import of the device around the world to ensure its increasing availability. As per the OEC 2023 report, pacemakers were valued at USD 7 billion with Switzerland being the top exporter at USD 1.8 billion and the United States being the top importer at USD 1.9 billion. In addition, the export growth of the device was 2.7% in 2023 and is currently ranked 314th in the Product Complexity Index (PCI), thus a positive outlook for paroxysmal atrial tachycardia market expansion.
Pacemakers Export/Import by Countries
|
Countries |
Export |
Import |
|
Ireland |
USD 1.3 billion |
- |
|
Netherlands |
USD 779 million |
USD 1.0 billion |
|
Malaysia |
USD 666 million |
- |
|
Singapore |
USD 605 million |
- |
|
Belgium |
- |
USD 457 million |
|
China |
- |
USD 429 million |
|
United Kingdom |
- |
USD 353 million |
Source: OEC 2023
Moreover, the provision of cardiovascular care is another factor bolstering the expansion of the paroxysmal atrial tachycardia market globally. Though it is expensive, there is the requirement of economic evaluation for the consumption of resources to ensure a suitable payer’s pricing of treatment services to patients suffering from the condition. In this regard, a cost analytical study was published by NLM in January 2022 for the treatment of cardiovascular disorders in a super-specialty hospital. The per bed per day pricing sustained by the hospital was USD 434 for patients in the cardiac care unit, USD 342 for the adult cardiology ward, and USD 289 for the pediatric cardiology ward, thus a positive outlook for the paroxysmal atrial tachycardia market growth.
Paroxysmal Atrial Tachycardia Sector: Growth Drivers and Challenges
Growth Drivers
- Increased adoption of catheter ablation: It is a suitable therapy for paroxysmal atrial tachycardia, providing accuracy and efficacy. As per an article published by the Johns Hopkins University in 2025, the success rate of the treatment is over 90%, depending on the type of arrhythmia being treated, highly driving the growth of the paroxysmal atrial tachycardia market. The procedure of the treatment involves the successful distribution of energy to dislocate the electrical trails triggering arrhythmia. This marginally invasive intervention diminishes the reappearance of PAT incidents and develops patient results, thus a suitable solution to combat the condition.
- Huge emphasis on cardiac treatment: Cardiac rehabilitation is advantageous for a wide range of individuals with heart conditions, assisting them to reclaim strength and condensing the risk of future cardiac events. According to an article published by Annals of Thoracic Surgery Short Reports in June 2024, over 1 million cardiac surgical procedures take place every year. There is the inclusion of healthy lifestyle adoption, emotional support, and exercise training as a part of the treatment program for patients. This, however, reduces the risk of future heart problems, thus suitable for the paroxysmal atrial tachycardia market.
Yearly Cardiac Surgery Volume per 100,000 Population
|
Surgical Process |
Procedural Volume |
|
|
|
Average |
Range |
|
All cardiac surgery |
123.2 |
27.3-271.5 |
|
Coronary artery bypass grafting |
36.7 |
7.7-64.5 |
|
Valve surgery |
30.8 |
12.7-55.2 |
|
Congenital heart surgery |
7.9 |
1.2-18.2 |
Source: Annals of Thoracic Surgery Short Reports June 2024
Challenges
- High cost of advanced treatment modalities: There has been a rise in therapeutic costs owing to advanced treatments including the use of wearable cardiac devices, hindering the growth of the paroxysmal atrial tachycardia market. These interventions frequently require considerable investment in terms of technology, skilled professionals, and post-procedural care. Based on an article published by NLM in August 2023, the cost of cardiac resynchronization therapy (CRT) is USD 4273.8 with a dual chamber and USD 2032.8 with a single chamber, abruptly more expensive than conventional pacemakers.
- Risk of infection : Patients undergoing surgery or treatments can suffer from infections, pain, and risk of bleeding, which is another challenge for the paroxysmal atrial tachycardia market. These are possible due to a lack of appropriate health infrastructure and intricate attention on additional disorders by emerging countries. In addition, improper training of healthcare providers, especially interns, often leads to the occurrence of unwanted infections. Also, the aspect of patient sensitivity due to the presence of any rare disease symptoms results in improper treatment.
Paroxysmal Atrial Tachycardia Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
6.9% |
|
Base Year Market Size (2024) |
USD 6.4 billion |
|
Forecast Year Market Size (2037) |
USD 15.2 billion |
|
Regional Scope |
|
Paroxysmal Atrial Tachycardia Segmentation
Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Based on the distribution channel segment is expected to capture paroxysmal atrial tachycardia market share of around 47.7% by the end of 2037. The evolution of this segment is fueled by the supply of medications for immediate care and rapid fulfillment of prescriptions. Hospital pharmacies usually comprise a particular unit for machines unraveling blisters and stuffing drugs into separate packages, as well as a separate administrative area with a station for analyzing medical orders. This results in saving time up to 25% for pharmacists, as stated in an article published by NLM in February 2023, which is driving the segment’s growth.
Diagnosis (Electrocardiogram (ECG), Holter Monitoring, Event Monitoring)
The electrocardiogram (ECG) segment is expected to influence the paroxysmal atrial tachycardia market at a considerable rate during the forecast timeline. As per the Journal of Electrocardiology article published in August 2022, more than 300 million ECG evaluations take place every year, which are performed by trained technicians in healthcare facilities. Besides, with digitalization and innovation, there has been the incorporation of artificial intelligence that resulted in the formation of AI-enabled electrocardiography readily used to forecast the risk of future disease and mortality but has not yet been adopted into clinical practice. Therefore, with such development, the segment is poised to expand during the forecast period.
Our in-depth analysis of the global market includes the following segments:
|
Type |
|
|
Diagnosis |
|
|
Distribution Channel |
|
|
End user |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportParoxysmal Atrial Tachycardia Industry - Regional Synopsis
North America Market Analysis
North America in paroxysmal atrial tachycardia market is predicted to capture around 37.5% revenue share by the end of 2037. The population of the region is extremely aware of heart attacks based on which there has been technological advancement in healthcare facilities. According to the March 2024 New York State Government report, almost 805,000 people suffer from the attack every year, and out of these, 605,000 suffer for the first time, and the remaining 200,000 account to have a second attack. The partnership between hospitals and healthcare professionals is readily catering to integrated care services within the region.
The U.S. paroxysmal atrial tachycardia market has been gaining traction due to the involvement of the U.S. FDA in initiating approvals of drugs and treatment options for the condition. For instance, in October 2024, Boston Scientific declared the U.S. FDA approval for its navigation-enabled ablation catheter for the treatment of paroxysmal atrial fibrillation and 510(k) clearance for new imaging software for its pulsed field ablation system. After the approval, the organization broadcasted the abrupt commercial launch of its ablation catheter and imaging software, thus having a positive impact on the market.
The paroxysmal atrial tachycardia market in Canada is witnessing significant growth owing to investments initiated by the Government and administrative bodies to keep a check on the spread of heart diseases. For instance, as per the May 2022 Government of Canada report, there has been funding of USD 5 million by the Parliamentary Secretary to the Minister of Health. The purpose was to sustain the latest national research network that emphasized on improving the prevention, diagnosis, treatment, and care of heart failure across the country. Besides, more than a million dollars has been invested by the Public Health Agency and the University of Ottawa Heart Institute Foundation for cardiovascular disease prevention and care network for women, as stated in the February 2023 University of Ottawa Heart Institute article.
APAC Market Statistics
The paroxysmal atrial tachycardia market in APAC is the fastest-growing region and is poised to witness lucrative growth during the forecast timeline. The presence of progressive healthcare systems and the high occurrence of cardiovascular diseases support strong market performance. As per the September 2023 WHO report, there have been 3.8 billion deaths due to cardiovascular disorders, especially in South East Asia. To overcome the spread in the region, there is the provision of drug treatment catering to effectively managing high blood lipids, diabetes, and hypertension, which eventually results in the reduction of heart diseases.
The paroxysmal atrial tachycardia market in India is expecting substantial growth owing to the availability of treatment options. According to the June 2024 Asia Heart Institute Organization article, a heart rate surpassing 100 beats per minute is denoted as tachycardia in medical terms. To combat this, there are appropriate medical solutions available in Mumbai with hospitals ranging from Nanavati Hospital to Gleneagles Hospitals, Kokilaben Dhirubhai Ambani Hospital, Fortis Hospital Mulund, and many more. Also, implantable cardiac defibrillator (ICD), cardioversion, Paroxysmal supraventricular tachycardia (PSVT), and supraventricular tachycardia are a few treatment options readily available in the city.
The paroxysmal atrial tachycardia market in China is gaining exposure since atrial fibrillation has arisen as a prominent public health issue due to the aging population and rapid urbanization. Besides, pulsed-field ablation has achieved consideration in cardiac electrophysiology in the country and a clinical study was published by NLM in December 2024 to evaluate the probability and well-being of PFA and its combination with radiofrequency ablation for treating paroxysmal supraventricular tachycardia. A total of 158 patients were part of the study, wherein the acute ablation was successful among 99.3% of patients, thus denoting an appropriate treatment option for the condition among the regional population.
Companies Dominating the Paroxysmal Atrial Tachycardia Landscape
- Abbott Laboratories
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- AbbVie Inc.
- AtriCure, Inc.
- Biosense Webster, Inc.
- Boston Scientific Corporation
- Bristol-Myers Squibb
- Hansen Medical
- iRhythm Technologies, Inc.
- Johnson & Johnson
- Medtronic PLC
- Milestone Pharmaceuticals
- Philips Healthcare
- Sanofi S.A.
- Vektor Medical
Companies dominating the paroxysmal atrial tachycardia market are gaining rapid exposure due to the latest innovations in medical solutions to aid the condition globally. In addition, a few organizations are aiming to expand their services in global markets to create awareness of the disorder and cater to patients. Also, the aspect of organizational funding is highly driving the market expansion internationally. For instance, in May 2023, Milestone Pharmaceuticals Inc. proclaimed that it entered into a USD 125 million strategic funding agreement with existing shareholders, RTW investments, LP, and certain of its affiliates.
Moreover, with this agreement, an additional funding of USD 64.6 million of cash, cash equivalents, and short-term investments are expected to fund Milestone's operations into the middle of 2025, including the potential approval and launch of etripamil. Besides, etripamil is the organization's investigational calcium channel blocker projected to authorize patients with paroxysmal supraventricular tachycardia (PSVT) to treat their attacks outside of the emergency department. Therefore, with such investment from companies, the paroxysmal atrial tachycardia market is expected to amplify within the forecast period.
Here's the list of some key players:
In the News
- In September 2024, Vektor Medical unveiled groundbreaking research on artificial intelligence (AI) and deep learning innovations in ventrivular tachycardia analysis at HRX 2024 to provide crucial insights for electrophysiologists performing ablation procedures.
- In May 2024, Medtronic declared the regulatory approval of its PulseSelect pulsed field ablation (PFA) system in Japan, expanding the global reach of the proven safe and effective technology for the treatment of paroxysmal and persistent atrial fibrillation (AFib) patients.
- In January 2024, Biosense Webster, Inc., part of Johnson & Johnson MedTech, notified the approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for the VARIPULSE platform for the treatment of symptomatic drug refractory recurrent paroxysmal atrial fibrillation (AFib) by utilizing pulsed-field ablation (PFA).
Author Credits: Radhika Pawar
- Report ID: 7339
- Published Date: Mar 18, 2025
- Report Format: PDF, PPT
